Mithra Sritharan

Mithra Sritharan

Auto-generated profile, based on publicly available information

Mithra Sritharan

Department of Hepatobiliary Surgery, Monash Health, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
JTJonathan Tiong
Jonathan Tiong
ARAshray Rajagopalan
Ashray Rajagopalan
JJJoseph Jaya
Joseph Jaya
MSMithra Sritharan
Mithra Sritharan
A mid-50s woman presented with acute right upper quadrant pain 1-day post second cycle of pembrolizumab. She has a significant history for two concurrent malignancies: a solitary oligometastatic hepatic melanoma (NRAS mutant) of unknown primary diagnosed 2 months prior, and a 10-year history of breast carcinoma with pulmonary metastases on palliative chemotherapy. Multiphase CT scan demonstrated active venous bleeding without active arterial bleeding. The patient received two units of packed red blood cells, followed by selective transcatheter arterial embolisation (TAE) of the right hepatic artery branches to segment 7 and 8. Spontaneous rupture of solitary liver metastases are exceedingly rare. TAE is a safe and effective treatment choice in patients with spontaneous rupture. Given progressive tumour burden, changes in management with a different immunotherapy agent can be considered.

23 June 2026 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Closed access
RGRathin Gosavi
Rathin Gosavi
MSMithra Sritharan
Mithra Sritharan
SBStephen W. Bell
Stephen W. Bell
PMPaul McMurrick
Paul McMurrick
WTWilliam Teoh
William Teoh
VNVignesh Narasimhan
Vignesh Narasimhan
Perioperative chemotherapy is frequently used for resectable colorectal liver metastases (CRLM), despite persistent uncertainty regarding the extent of its survival benefit. This perspective revisits the evidence supporting this practice and asks whether upfront liver-directed treatment should be more strongly considered in selected patients. A central paradox underpins this debate: although adjuvant chemotherapy improves OS in stage III colon cancer, randomized trials in resectable CRLM have consistently failed to demonstrate an OS advantage for perioperative or adjuvant systemic therapy. Instead, chemotherapy primarily appears to delay recurrence while exposing patients to potential harms. These harms include treatment-related hepatic injury, increased perioperative morbidity, and, in some cases, progression during induction therapy that may preclude curative resection. Several explanations may account for this discrepancy, including clonal selection of resistant disease, the influence of the hepatic metastatic microenvironment, and the availability of salvage local therapy at recurrence. Nevertheless, systemic therapy remains relevant in selected patients with technically or biologically complex disease, such as those requiring staged liver surgery, downsizing for resectability, or treatment sequencing in synchronous primary and liver disease. Additionally, thermal ablation is emerging as a valid early liver-directed option for carefully selected small-volume metastases. Looking forward, circulating tumor DNA and other molecular tools may better identify the subgroup most likely to benefit from perioperative treatment. Treatment sequencing in resectable CRLM should therefore be guided by anatomy, tumour biology, and emerging molecular markers of residual risk, with systemic therapy used selectively rather than as a universal default.